Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

69.750
+0.1000.14%
Volume:865.68K
Turnover:60.68M
Market Cap:37.87B
PE:40.74
High:72.250
Open:70.000
Low:68.600
Close:69.650
52wk High:92.000
52wk Low:23.000
Shares:543.00M
HK Float Shares:346.07M
Volume Ratio:0.66
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.712
ROE:23.72%
ROA:4.45%
PB:8.43
PE(LYR):40.74
PS:5.01

Loading ...

Shanghai Henlius Biotech FY2025 revenue rose 16.5% to RMB6.67 billion, R&D expenditure jumped 35.4% to RMB2.49 billion

Reuters
·
Mar 20

Shanghai Henlius Biotech FY Revenue RMB 6,666.6 Million

THOMSON REUTERS
·
Mar 20

Shanghai Henlius Biotech wins NMPA IND approval for HLX18 phase 1 trial in multiple solid tumors

Reuters
·
Mar 20

Shanghai Henlius Biotech Inc - Nmpa Approves Ind Application for Phase 1 Trial of Nivolumab Biosimilar Hlx18

THOMSON REUTERS
·
Mar 20

HENLIUS Appoints Chen Xiuling as Joint Company Secretary, Authorized Representative, and Agent for Legal Process

Stock News
·
Mar 20

Shanghai Henlius appoints Chan Sau Ling as joint company secretary and authorised representative

Reuters
·
Mar 20

HENLIUS CEO Zhu Jun on AI: Invaluable in Drug R&D, Ultimate Goal is a Lab-Free Future

Deep News
·
Mar 19

HENLIUS CEO Zhu Jun on the 'First Principle' in Pharma: Daring to Tackle Challenges Others Avoid

Deep News
·
Mar 18

Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17

Stock News
·
Mar 17

BRIEF-Shanghai Henlius Biotech Inc Says NMPA Approves IND Application For Hlx07 And Hansizhuang Combination In SQNSCLC

Reuters
·
Mar 16

HENLIUS Obtains NMPA Clearance for Clinical Trial of Pimurutamab HLX07 Combination Therapy in Advanced Squamous Non-Small Cell Lung Cancer

Stock News
·
Mar 16

Shanghai Henlius Biotech Inc - Nmpa Approves Ind Application for Hlx07 and Hansizhuang Combination in Sqnsclc

THOMSON REUTERS
·
Mar 16

NMPA approves Henlius IND trial of HLX07 combo for advanced squamous NSCLC

Reuters
·
Mar 16

BUZZ-Shanghai Henlius Biotech rises most in 5 months on new drug application

Reuters
·
Mar 10

HENLIUS Shares Surge Over 8% Following Clinical Trial Approval for Innovative Cancer Treatment

Stock News
·
Mar 10

Assessing Shanghai Henlius Biotech’s Valuation As HLX11 And HLX22 Breast Cancer Programs Gain Momentum

Simply Wall St.
·
Mar 09

BRIEF-Shanghai Henlius Biotech Says NMPA Approves IND Application For Phase 1 Trial HLX316

Reuters
·
Mar 09

Henlius (02696) Secures NMPA IND Approval for First-in-Class Tetra-Specific Antibody HLX3901 Targeting Advanced Solid Tumours

Bulletin Express
·
Mar 09

Henlius (02696): NMPA Approves IND for First-in-Class B7-H3-Targeting Sialidase Fusion Protein HLX316 in Advanced Solid Tumours

Bulletin Express
·
Mar 09

HENLIUS Gains NMPA Clearance for Phase 1 Trial of HLX3901 in Advanced/Metastatic Solid Tumors

Stock News
·
Mar 09